Is Omarigliptin on the market?

Omarigliptin (Omarigliptin) 25 mg and 12.5 mg tablets were approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) on September 28, 2015. Japan is the first country to approve ologliptin, which is a potent, long-acting DPP-4 inhibitor oral anti-diabetic drug for the once-weekly treatment of type 2 diabetes. It is currently developed by Merck & Co. (Merck & Co.). It is understood that Merck has announced that the company will not submit marketing applications in the United States and Europe.

Dipeptidyl PeptidaseIV (DPP-4) Inhibitors improve glycemic control in patients with type 2 diabetes by extending the half-life of incretin peptides, which stimulate insulin secretion and reduce glucagon release in a glucose-dependent manner. Studies of daily doses of DPP-4 inhibitors have demonstrated favorable efficacy, safety and tolerability as monotherapy and as add-ons to other antihyperglycemic agents (AHAs). The half-life of ologliptin supports weekly dosing. The availability of once-weekly oral ologliptin may represent a paradigm shift in the treatment of type 2 diabetes. Database analysis suggests that weekly oral ologliptin, which is effective, safe, and well-tolerated, may help improve medication compliance in some patients with type 2 diabetes.

The original drug Ologliptin is not marketed in the country and is therefore not included in medical insurance. The price of each box of generic Ologliptin drugs currently on the market overseas may be more than more than 1,000 yuan (the price may fluctuate due to exchange rates), and its drug ingredients are basically the same as those of the original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.